Entero Therapeutics (ENTO) Competitors $0.39 -0.01 (-1.26%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. PMCB, ORGS, CLDI, ARTL, APLM, CVM, SLXN, OMGA, CELZ, and AIMShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Nuvilex (PMCB), Orgenesis (ORGS), Calidi Biotherapeutics (CLDI), Artelo Biosciences (ARTL), Apollomics (APLM), CEL-SCI (CVM), Silexion Therapeutics (SLXN), Omega Therapeutics (OMGA), Creative Medical Technology (CELZ), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors Nuvilex Orgenesis Calidi Biotherapeutics Artelo Biosciences Apollomics CEL-SCI Silexion Therapeutics Omega Therapeutics Creative Medical Technology AIM ImmunoTech Nuvilex (NASDAQ:PMCB) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Which has preferable earnings & valuation, PMCB or ENTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvilexN/AN/A$330K$0.741.53Entero TherapeuticsN/AN/A-$18.06MN/AN/A Is PMCB or ENTO more profitable? Nuvilex's return on equity of 0.51% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvilexN/A 0.51% 0.35% Entero Therapeutics N/A -1,063.82%-26.06% Which has more volatility & risk, PMCB or ENTO? Nuvilex has a beta of -0.42, suggesting that its stock price is 142% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Do insiders & institutionals have more ownership in PMCB or ENTO? 34.2% of Nuvilex shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 10.2% of Nuvilex shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer PMCB or ENTO? In the previous week, Nuvilex's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score. Company Overall Sentiment Nuvilex Neutral Entero Therapeutics Neutral SummaryNuvilex beats Entero Therapeutics on 5 of the 6 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.90M$2.89B$5.48B$8.94BDividend YieldN/A2.44%5.24%4.05%P/E RatioN/A20.6427.3120.15Price / SalesN/A192.11372.7693.81Price / CashN/A41.7026.2128.59Price / Book-0.497.417.975.61Net Income-$18.06M-$55.04M$3.17B$248.49M7 Day Performance1.92%4.08%2.72%6.17%1 Month Performance-23.46%1.24%2.15%7.89%1 Year Performance-61.73%4.56%33.95%21.19% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$0.40+0.3%N/A-62.9%$1.90MN/A0.009PMCBNuvilex0.8957 of 5 stars$1.14+4.6%N/A-47.4%$7.48MN/A1.544Positive NewsHigh Trading VolumeORGSOrgenesisN/A$1.53+3.7%N/AN/A$7.34M$662K0.00150Gap DownCLDICalidi Biotherapeutics0.3429 of 5 stars$0.23flatN/A-87.9%$7.31M$50K0.0038News CoverageARTLArtelo Biosciences2.9632 of 5 stars$9.50-28.4%$33.00+247.4%+78.8%$7.26MN/A-0.535News CoverageAnalyst UpgradeGap UpHigh Trading VolumeAPLMApollomics0.3398 of 5 stars$6.38-2.8%N/A-66.3%$7.24M$1.49M0.0045Positive NewsCVMCEL-SCI0.0808 of 5 stars$2.37+3.5%N/A-93.7%$7.19MN/A-4.9443News CoverageSLXNSilexion TherapeuticsN/A$0.80-1.0%$5.00+523.2%N/A$7.04MN/A0.00N/AOMGAOmega Therapeutics2.1075 of 5 stars$0.13-21.8%$8.50+6,700.0%-93.0%$6.92M$8.10M-0.09120Gap UpCELZCreative Medical TechnologyN/A$2.64-0.4%N/A-30.4%$6.85M$10K-0.695Positive NewsAIMAIM ImmunoTech1.6679 of 5 stars$8.93+3.2%$275.00+2,981.2%-76.6%$6.82M$146K-18.9920 Related Companies and Tools Related Companies Nuvilex Competitors Orgenesis Competitors Calidi Biotherapeutics Competitors Artelo Biosciences Competitors Apollomics Competitors CEL-SCI Competitors Silexion Therapeutics Competitors Omega Therapeutics Competitors Creative Medical Technology Competitors AIM ImmunoTech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA “starter home” for $1925?An MIT startup just slashed the cost of producing the world’s most valuable metal — by 99%. This “miracle m...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTO Stock Alerts